Labomar Logo

Labomar

A full-service CDMO for supplements, medical devices, and dermo-cosmetic products.

LBM | XMIL

Overview

Corporate Details

ISIN(s):
IT0005421646
LEI:
815600BD66DA7878FF03
Country:
Italy
Address:
VIA NAZARIO SAURO, 35/I, 31036 ISTRANA

Description

Labomar is a Contract Development and Manufacturing Organization (CDMO) that specializes in creating and producing food supplements, medical devices, foods for special medical purposes (FSMPs), and dermo-cosmetic products. The company operates as a full-service, one-stop-shop partner, offering customized development of bespoke products and ready-to-market formulations. Labomar leverages patented and advanced technologies with a strong emphasis on scientific research and innovation to manufacture high-quality products. Its services cover the entire product lifecycle, from formulation and the production of plant extracts to manufacturing and regulatory support for its clients.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2021-11-24 16:05
Labomar SpA partecipa il 1° dicembre alla Mid&Small in Milan 2021
Italian 651.5 KB
2021-11-23 16:36
Labomar holds 100% of Labiotre
English 625.2 KB
2021-11-23 16:33
Labomar controlla al 100% Labiotre Srl
Italian 625.8 KB
2021-10-20 08:28
Labomar Investor Days_October 18-19,2021
English 21.9 MB
2021-10-12 10:35
New variation of Labomar Spa Financial Calendar
English 675.1 KB
2021-10-12 10:33
Nuova variazione Calendario Finanziario Labomar Spa
Italian 628.0 KB
2021-09-28 14:27
Notes to Press Release of 28.09.2021
English 545.3 KB
2021-09-28 14:25
Nota Stampa al Comunicato del 27.09.2021
Italian 545.3 KB
2021-09-27 17:02
Economic and Financial Consolidated Results 1H2021 - Labomar Presentation
English 2.6 MB
2021-09-27 16:59
Labomar_1H 2021 Consolidated Results
English 1.1 MB
2021-09-27 16:57
Labomar_Risultati Consolidati 1H 2021
Italian 1.0 MB
2021-09-24 15:44
Labomar is attending ISMO 2021
English 753.6 KB
2021-09-24 15:43
Labomar S.p.A. partecipa a ISMO 2021
Italian 770.9 KB
2021-09-16 08:20
Labomar Spa stake in Labiotre Srl rises to 48.8%
English 552.4 KB
2021-09-16 08:19
Labomar Spa sale al 48,8% di Labiotre Srl
Italian 193.3 KB

Automate Your Workflow. Get a real-time feed of all Labomar filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Labomar

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Labomar via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.